Current and potential inflammation targeted therapies in head and neck cancer.
about
Bioactive Compounds Isolated from Microalgae in Chronic Inflammation and CancerLinks demystified: Periodontitis and cancerCombination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer.Salvianolic Acid B, a potential chemopreventive agent, for head and neck squamous cell cancer.Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression.Human β-defensin 3 promotes NF-κB-mediated CCR7 expression and anti-apoptotic signals in squamous cell carcinoma of the head and neck.Gα₁₂ drives invasion of oral squamous cell carcinoma through up-regulation of proinflammatory cytokinesThe molecular pathogenesis of head and neck cancer.HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress.Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers.A role of sphingosine kinase 1 in head and neck carcinogenesisMet tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinomaNerve growth factor links oral cancer progression, pain, and cachexia.IKK phosphorylation of NF-κB at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancerHSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma.Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer modelSolid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models.A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.Mononuclear phagocytes in head and neck squamous cell carcinoma.Therapeutic strategies for head and neck cancer based on p53 status.Molecular communication between tumor-associated fibroblasts and head and neck squamous cell carcinoma.The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas.Candida albicans and cancer: Can this yeast induce cancer development or progression?NF-κB in cancer therapy.Involvement of CD74 in head and neck squamous cell carcinomas.Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells.Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines.Neurocognitive function in head and neck cancer patients prior to treatment.The association and prognostic relevance of cancerous inhibitor of protein phosphatase 2A and inflammation in tongue squamous cell carcinoma.High S100A8 and S100A12 protein expression is a favorable prognostic factor for survival of oropharyngeal squamous cell carcinoma.
P2860
Q26782065-7FAF07D7-ACB9-485B-8F28-355238407E99Q26865599-C6DC3813-723A-4196-8A2E-C65028DF29F9Q33895607-AAD20B3A-5290-42A5-A563-25F0E3AFA28DQ33900846-AEB9EC96-2B1E-4EFB-96AF-A1E49E69C1BFQ34442838-7CD85E3D-4C6C-4FC2-BAC1-0BCDE7F6C1B2Q34462187-57F7F7E6-1F3B-49FC-9918-7F7A5A0E6EEFQ34520408-70A91DD4-6BEC-4BDB-861C-21BC2A08AB9BQ34770537-99C62EFF-EF9D-4997-A131-348337E2259CQ35111736-84C7A2BE-4957-4497-BA7E-174A213A1521Q35620220-1EE60A4C-324D-45B6-8ABA-D9B657F83421Q35741628-36F606C3-1D35-43B4-B27A-195457CADD54Q35929414-E12C711A-B8DC-4F70-BC4F-4B00F097C0BDQ36014988-DDF98520-3E61-46D9-BE6F-246717EAD021Q36031474-B789444F-D995-41C2-8388-6DA031783B6AQ36309403-4D6A5A93-0540-4B8C-A992-BAAE24BD9C47Q37060950-C64858C7-6BA0-42CD-AC0A-E7CBB1B34C55Q37146678-5E8D6A92-A14F-4524-B506-B47DA6015709Q37327348-B92CDB82-2559-48DE-9F36-DB30D3ACDADEQ37362560-D603DCDB-3C3D-4DCC-A269-783966A10F82Q37646333-55CE5943-EE55-43AB-A0FD-69B65D57B792Q38042630-699E94FF-728D-41CE-983A-B8E3529C2220Q38077373-1109029A-16FF-4C63-8706-7F87A9AD22D2Q38079588-DD14A0C3-70A2-4DFE-B08B-7C7DDC0CF5ABQ38223120-16BF93E0-2BF7-44D6-A009-B99FE5A329B4Q38359190-AD4520DE-73B9-456D-B627-8A4C86F3FE36Q38450133-089DCE4E-80CE-4D68-B37D-9F41296A4A74Q39069156-B7A62AC9-CA16-4E88-AFC1-C527599651FCQ39630347-7400A006-B9E3-4FA1-BB7E-D10F067F0B8EQ39794213-5474F64E-3068-42C4-9AAE-1F9DA46C80EBQ41160985-D98848A5-705A-4209-B97F-664F79CAA4ECQ42466919-32E46DD8-D1C0-4B36-89F5-54D810FF2D46
P2860
Current and potential inflammation targeted therapies in head and neck cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current and potential inflammation targeted therapies in head and neck cancer.
@en
Current and potential inflammation targeted therapies in head and neck cancer.
@nl
type
label
Current and potential inflammation targeted therapies in head and neck cancer.
@en
Current and potential inflammation targeted therapies in head and neck cancer.
@nl
prefLabel
Current and potential inflammation targeted therapies in head and neck cancer.
@en
Current and potential inflammation targeted therapies in head and neck cancer.
@nl
P2093
P2860
P1476
Current and potential inflammation targeted therapies in head and neck cancer.
@en
P2093
Carter Van Waes
Frederick Wang
Jay Friedman
Pattatheyil Arun
Zhong Chen
P2860
P304
P356
10.1016/J.COPH.2009.06.005
P577
2009-06-29T00:00:00Z